{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:03:12Z","timestamp":1789380192561,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tokyo University of Science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Novel cannabinoids, including tetrahydrocannabihexol (THCH), tetrahydrocannabivarin (THCV), hexahydrocannabinol (HHC), hexahydrocannabihexol (HHCH), and hexahydrocannabiphorol (HHCP), have raised toxicological concerns, but their acute neurobehavioral effects remain poorly understood. This study compared the in vivo potencies of six cannabinoids using locomotor suppression and catalepsy-like immobility as indices of psychomotor suppression and toxic motor impairment, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Male C57BL\/6J mice received intraperitoneal administration of \u03949-tetrahydrocannabinol (THC), HHC, THCH, THCV, HHCH, or HHCP. Catalepsy-like immobility was assessed using the bar test 20 min after dosing (maximum latency, 300 s), and spontaneous locomotor activity was recorded for 10 min beginning 35 min after dosing. ED50 values were determined for locomotor suppression and catalepsy-like immobility, and the Hazard Proximity Index (HPI, %) was calculated as (ED50_locomotor \/ ED50_catalepsy) \u00d7 100, with higher values indicating a narrower behavioral safety margin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All cannabinoids reduced spontaneous locomotor activity. THC, THCH, HHCH, and HHCP produced robust catalepsy-like immobility, whereas HHC induced only weak, non-significant immobility. THCV increased immobility only at higher doses and did not reach 50% catalepsy within the tested dose range. HPI values were 25.6% for THC, 45.1% for THCH, 5.1% for HHC, 33.2% for HHCH, and 3.7% for HHCP; HPI was not calculated for THCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Psychomotor suppression occurred at lower doses than catalepsy-like toxicity. Some side-chain-extended cannabinoids, particularly THCH and HHCH, showed a narrower separation between these endpoints. These findings provide comparative ED50 benchmarks and introduce the HPI as a novel ED50-based screening metric for the relative prioritization of emerging cannabinoids in forensic toxicology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11419-026-00786-z","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:09:05Z","timestamp":1789376945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging cannabinoids differ in behavioral safety margins in mice: a comparative hazard proximity analysis of locomotor suppression and catalepsy-like immobility"],"prefix":"10.1007","author":[{"given":"Shintaro","family":"Shirakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Tokeshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8617-2441","authenticated-orcid":false,"given":"Akiyoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"786_CR1","doi-asserted-by":"publisher","first-page":"9.59.1","DOI":"10.1002\/CPNS.31","volume":"80","author":"M Metna-Laurent","year":"2017","unstructured":"Metna-Laurent M, Mond\u00e9sir M, Grel A et al (2017) Cannabinoid-induced tetrad in mice. Curr Protoc Neurosci 80:9.59.1-9.59.10. https:\/\/doi.org\/10.1002\/CPNS.31","journal-title":"Curr Protoc Neurosci"},{"key":"786_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/S00213-021-05995-5","volume":"239","author":"CF Moore","year":"2022","unstructured":"Moore CF, Weerts EM (2022) Cannabinoid tetrad effects of oral \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations. Psychopharmacology 239:1397\u20131408. https:\/\/doi.org\/10.1007\/S00213-021-05995-5","journal-title":"Psychopharmacology"},{"key":"786_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1254\/JJP.87.297","volume":"87","author":"K Mishima","year":"2001","unstructured":"Mishima K, Egashira N, Hirosawa N et al (2001) Characteristics of learning and memory impairment induced by delta9-tetrahydrocannabinol in rats. Jpn J Pharmacol 87:297\u2013308. https:\/\/doi.org\/10.1254\/JJP.87.297","journal-title":"Jpn J Pharmacol"},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/SJ.NPP.1300496","volume":"29","author":"DC D\u2019Souza","year":"2004","unstructured":"D\u2019Souza DC, Perry E, MacDougall L et al (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558\u20131572. https:\/\/doi.org\/10.1038\/SJ.NPP.1300496","journal-title":"Neuropsychopharmacology"},{"key":"786_CR5","doi-asserted-by":"publisher","first-page":"E2657","DOI":"10.1073\/PNAS.1206820109\/SUPPL_FILE\/ST03.DOCX","volume":"109","author":"MH Meier","year":"2012","unstructured":"Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109:E2657\u2013E2664. https:\/\/doi.org\/10.1073\/PNAS.1206820109\/SUPPL_FILE\/ST03.DOCX","journal-title":"Proc Natl Acad Sci USA"},{"key":"786_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","volume":"278","author":"VM Showalter","year":"1996","unstructured":"Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989\u2013999. https:\/\/doi.org\/10.1016\/S0022-3565(25)20744-3","journal-title":"J Pharmacol Exp Ther"},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/J.BMC.2004.09.050","volume":"13","author":"JW Huffman","year":"2005","unstructured":"Huffman JW, Zengin G, Wu MJ et al (2005) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem 13:89\u2013112. https:\/\/doi.org\/10.1016\/J.BMC.2004.09.050","journal-title":"Bioorg Med Chem"},{"key":"786_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/JMS.1558","volume":"44","author":"V Auw\u00e4rter","year":"2009","unstructured":"Auw\u00e4rter V, Dresen S, Weinmann W et al (2009) \u201cSpice\u201d and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832\u2013837. https:\/\/doi.org\/10.1002\/JMS.1558","journal-title":"J Mass Spectrom"},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1476-5381.2009.00582.x","volume":"160","author":"BK Atwood","year":"2010","unstructured":"Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of \u201cSpice\u201d herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585\u2013593. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00582.x","journal-title":"Br J Pharmacol"},{"key":"786_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0022-3565(25)38122-X","volume":"265","author":"DR Compton","year":"1993","unstructured":"Compton DR, Rice KC, De Costa BR et al (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218\u2013226. https:\/\/doi.org\/10.1016\/S0022-3565(25)38122-X","journal-title":"J Pharmacol Exp Ther"},{"key":"786_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0022-3565(25)10783-0","volume":"262","author":"LH Gold","year":"1992","unstructured":"Gold LH, Balster RL, Barrett RL et al (1992) A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharmacol Exp Ther 262:479\u2013486. https:\/\/doi.org\/10.1016\/S0022-3565(25)10783-0","journal-title":"J Pharmacol Exp Ther"},{"key":"786_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/J.1527-3458.2001.TB00192.X","volume":"7","author":"A Ottani","year":"2006","unstructured":"Ottani A, Giuliani D (2006) HU 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 7:131. https:\/\/doi.org\/10.1111\/J.1527-3458.2001.TB00192.X","journal-title":"CNS Drug Rev"},{"key":"786_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.PBB.2014.05.010","volume":"124","author":"R Marshell","year":"2014","unstructured":"Marshell R, Kearney-Ramos T, Brents LK et al (2014) In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid \u03949-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav 124:40\u201347. https:\/\/doi.org\/10.1016\/J.PBB.2014.05.010","journal-title":"Pharmacol Biochem Behav"},{"key":"786_CR14","first-page":"128","volume":"49","author":"Y Iketani","year":"2024","unstructured":"Iketani Y, Morita S, Tsuji T et al (2024) A case of acute intoxication from sublingually administering a liquid inhalation product containing a marijuana analogue. Tokai J Exp Clin Med 49:128\u2013132","journal-title":"Tokai J Exp Clin Med"},{"key":"786_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/J.TOXREP.2025.101912","volume":"14","author":"R Thomsen","year":"2025","unstructured":"Thomsen R, Axelsen TM, L\u00f8kken N et al (2025) Prolonged sedation and unconsciousness after intoxication with the novel semisynthetic cannabinoid hexahydrocannabioctyl (HHC-C8): two case descriptions. Toxicol Rep 14:101912. https:\/\/doi.org\/10.1016\/J.TOXREP.2025.101912","journal-title":"Toxicol Rep"},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1017\/S1461145709990605","volume":"13","author":"LE Long","year":"2010","unstructured":"Long LE, Chesworth R, Huang XF et al (2010) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL\/6JArc mice. Int J Neuropsychopharmacol 13:861\u2013876. https:\/\/doi.org\/10.1017\/S1461145709990605","journal-title":"Int J Neuropsychopharmacol"},{"key":"786_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/SJ.BJP.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199\u2013215. https:\/\/doi.org\/10.1038\/SJ.BJP.0707442","journal-title":"Br J Pharmacol"},{"key":"786_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/S00213-011-2415-0\/FIGURES\/8","volume":"219","author":"S Deiana","year":"2012","unstructured":"Deiana S, Watanabe A, Yamasaki Y et al (2012) Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u0394 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology 219:859\u2013873. https:\/\/doi.org\/10.1007\/S00213-011-2415-0\/FIGURES\/8","journal-title":"Psychopharmacology"},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1124\/JPET.120.265892\/-\/DC1","volume":"374","author":"A Torrens","year":"2020","unstructured":"Torrens A, Vozella V, Huff H et al (2020) Comparative pharmacokinetics of \u03949-tetrahydrocannabinol in adolescent and adult male mice. J Pharmacol Exp Ther 374:151\u2013160. https:\/\/doi.org\/10.1124\/JPET.120.265892\/-\/DC1","journal-title":"J Pharmacol Exp Ther"},{"key":"786_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PBIO.0050269","volume":"5","author":"K Monory","year":"2007","unstructured":"Monory K, Blaudzun H, Massa F et al (2007) Genetic dissection of behavioural and autonomic effects of \u03949-tetrahydrocannabinol in mice. PLoS Biol 5:e269. https:\/\/doi.org\/10.1371\/JOURNAL.PBIO.0050269","journal-title":"PLoS Biol"},{"key":"786_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/FNBEH.2019.00032\/PDF","author":"CR Kasten","year":"2019","unstructured":"Kasten CR, Zhang Y, Boehm SL (2019) Acute cannabinoids produce robust anxiety-like and locomotor effects in mice, but long-term consequences are age- And sex-dependent. Front Behav Neurosci. https:\/\/doi.org\/10.3389\/FNBEH.2019.00032\/PDF","journal-title":"Front Behav Neurosci"},{"key":"786_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/S41386-020-00839-W","volume":"46","author":"CM Ruiz","year":"2021","unstructured":"Ruiz CM, Torrens A, Castillo E et al (2021) Pharmacokinetic, behavioral, and brain activity effects of \u03949-tetrahydrocannabinol in adolescent male and female rats. Neuropsychopharmacology 46:959\u2013969. https:\/\/doi.org\/10.1038\/S41386-020-00839-W","journal-title":"Neuropsychopharmacology"},{"key":"786_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/J.2042-7158.1988.TB05198.X","volume":"40","author":"EA Formukong","year":"1988","unstructured":"Formukong EA, Evans AT, Evans FJ (1988) Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L. J Pharm Pharmacol 40:132\u2013134. https:\/\/doi.org\/10.1111\/J.2042-7158.1988.TB05198.X","journal-title":"J Pharm Pharmacol"},{"key":"786_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0028-3908(88)90130-X","volume":"27","author":"RG Pertwee","year":"1988","unstructured":"Pertwee RG, Greentree SG (1988) Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology 27:485\u2013491. https:\/\/doi.org\/10.1016\/0028-3908(88)90130-X","journal-title":"Neuropharmacology"},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/J.NEUROSCIENCE.2007.10.026","volume":"151","author":"K Sano","year":"2008","unstructured":"Sano K, Mishima K, Koushi E et al (2008) \u03949-Tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience 151:320\u2013328. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2007.10.026","journal-title":"Neuroscience"},{"key":"786_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251330739","author":"JA Marusich","year":"2025","unstructured":"Marusich JA, Prioleau C, Akinfiresoye LR (2025) Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. J Psychopharmacol. https:\/\/doi.org\/10.1177\/02698811251330739","journal-title":"J Psychopharmacol"},{"key":"786_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/IJNP\/PYAF041","author":"K \u0160\u00edchov\u00e1","year":"2025","unstructured":"\u0160\u00edchov\u00e1 K, Mallarino B, Jane\u010dkov\u00e1 L et al (2025) Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. Int J Neuropsychopharmacol. https:\/\/doi.org\/10.1093\/IJNP\/PYAF041","journal-title":"Int J Neuropsychopharmacol"},{"key":"786_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0091-3057(91)90349-7","volume":"40","author":"BR Martin","year":"1991","unstructured":"Martin BR, Compton DR, Thomas BF et al (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471\u2013478. https:\/\/doi.org\/10.1016\/0091-3057(91)90349-7","journal-title":"Pharmacol Biochem Behav"},{"key":"786_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1602\/neurorx.2.4.554","volume":"2","author":"MS Alavijeh","year":"2005","unstructured":"Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM (2005) Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2:554\u2013571. https:\/\/doi.org\/10.1602\/neurorx.2.4.554","journal-title":"NeuroRx"},{"key":"786_CR30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/MOLECULES23061289","volume":"23","author":"I Zeiadeh","year":"2018","unstructured":"Zeiadeh I, Najjar A, Karaman R (2018) Strategies for enhancing the permeation of CNS-active drugs through the blood-brain barrier: a review. Molecules 23:1289. https:\/\/doi.org\/10.3390\/MOLECULES23061289","journal-title":"Molecules"},{"key":"786_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/DTA.3750","volume":"17","author":"M Persson","year":"2025","unstructured":"Persson M, Kronstrand R, Evans-Brown M, Green H (2025) In vitro activation of the CB1 receptor by the semi-synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC-O) and hexahydrocannabiphorol (HHC-P). Drug Test Anal 17:487\u2013493. https:\/\/doi.org\/10.1002\/DTA.3750","journal-title":"Drug Test Anal"},{"key":"786_CR32","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/S00204-024-03769-4","volume":"98","author":"LK Janssens","year":"2024","unstructured":"Janssens LK, Van Uytfanghe K, Williams JB et al (2024) Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with \u03b2-arrestin2 recruitment assays-and how this matters for the harm potential of seized drugs. Arch Toxicol 98:2619\u20132630. https:\/\/doi.org\/10.1007\/S00204-024-03769-4","journal-title":"Arch Toxicol"},{"key":"786_CR33","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/SJ.BJP.0706414","volume":"146","author":"A Thomas","year":"2005","unstructured":"Thomas A, Stevenson LA, Wease KN et al (2005) Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917\u2013926. https:\/\/doi.org\/10.1038\/SJ.BJP.0706414","journal-title":"Br J Pharmacol"},{"key":"786_CR34","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/J.1476-5381.2008.00107.X","volume":"156","author":"G Riedel","year":"2009","unstructured":"Riedel G, Fadda P, McKillop-Smith S et al (2009) Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156:1154\u20131166. https:\/\/doi.org\/10.1111\/J.1476-5381.2008.00107.X","journal-title":"Br J Pharmacol"},{"key":"786_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/NUTD.2013.9","author":"ET Wargent","year":"2013","unstructured":"Wargent ET, Zaibi MS, Silvestri C et al (2013) The cannabinoid \u0394(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. https:\/\/doi.org\/10.1038\/NUTD.2013.9","journal-title":"Nutr Diabetes"},{"key":"786_CR36","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2337\/DC16-0650","volume":"39","author":"KA Jadoon","year":"2016","unstructured":"Jadoon KA, Ratcliffe SH, Barrett DA et al (2016) Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 39:1777\u20131786. https:\/\/doi.org\/10.2337\/DC16-0650","journal-title":"Diabetes Care"},{"key":"786_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19\u201327. https:\/\/doi.org\/10.1177\/0269881112460109","journal-title":"J Psychopharmacol"},{"key":"786_CR38","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/bph.13000","volume":"172","author":"MG Cascio","year":"2015","unstructured":"Cascio MG, Zamberletti E, Marini P et al (2015) The phytocannabinoid, \u0394 9-tetrahydrocannabivarin, can act through 5-HT 1A receptors to produce antipsychotic effects. Br J Pharmacol 172:1305. https:\/\/doi.org\/10.1111\/bph.13000","journal-title":"Br J Pharmacol"},{"key":"786_CR39","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/J.1528-1167.2010.02523.X","volume":"51","author":"AJ Hill","year":"2010","unstructured":"Hill AJ, Weston SE, Jones NA et al (2010) \u03949-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51:1522\u20131532. https:\/\/doi.org\/10.1111\/J.1528-1167.2010.02523.X","journal-title":"Epilepsia"},{"key":"786_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/S002130100780","volume":"157","author":"V Sa","year":"2001","unstructured":"Sa V, Rj H, Br M, Ah L (2001) Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology 157:142\u2013150. https:\/\/doi.org\/10.1007\/S002130100780","journal-title":"Psychopharmacology"},{"key":"786_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1124\/JPET.104.080739","volume":"314","author":"SA Varvel","year":"2005","unstructured":"Varvel SA, Bridgen DT, Tao Q et al (2005) Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314:329\u2013337. https:\/\/doi.org\/10.1124\/JPET.104.080739","journal-title":"J Pharmacol Exp Ther"},{"key":"786_CR42","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1177\/0269881118799953","volume":"32","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Cortes-Briones JA, Surti T et al (2018) The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (\u03949-THC) in humans. J Psychopharmacol 32:1308\u20131318. https:\/\/doi.org\/10.1177\/0269881118799953","journal-title":"J Psychopharmacol"},{"key":"786_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2018.4841","volume":"1","author":"TR Spindle","year":"2018","unstructured":"Spindle TR, Cone EJ, Schlienz NJ et al (2018) Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open 1:e184841. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2018.4841","journal-title":"JAMA Netw Open"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-026-00786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-026-00786-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-026-00786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:09:07Z","timestamp":1789376947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-026-00786-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":43,"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1007\/s11419-026-00786-z","relation":{},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of Tokyo University of Science (approval numbers: Y22014 and Y24006) and were conducted in accordance with institutional guidelines and applicable regulations.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}